Experimental Considerations in Headspace Gas Chromatography - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experimental Considerations in Headspace Gas Chromatography
In this case study of amines, the authors discuss several parameters to be considered in developing a headspace GC method.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 76-79

Methods and materials

Instrumentation and sample materials. A gas chromatograph (Agilent 6890, Santa Clara, CA) with a G1888 (Agilent) headspace autosampler and 20-mL sample vials were used for the experiments. The column used for these amine analyses was a Restek RTX-5 AMINE (Bellefonte, PA), 30 m x 530 m x 5 m film thickness. Triethylamine (TEA) was purchased from FisherScientific (Division of Thermo Fisher Scientific, Waltham, MA); DMSO, n-butylamine, and allylamine were purchased from Sigma-Aldrich (St. Louis, MO); Water (high-performance liquid chromatography grade) was purchased from J.T. Baker (Phillipsburg, NJ); and dimethylformamide (DMF) was purchased from EMD Science (Darmstadt, Germany).


Table I: Headspace parameters
Stock TEA samples were prepared by diluting 138 L into 100 mL of diluent, where the diluent was different ratios of either DMSO:water or DMSO:0.01M sodium hydroxide (NaOH). Analysis samples were further diluted 1 mL into 100 mL with the appropriate diluent for the experiment. This dilution resulted in a final TEA concentration of 0.0100 mg/mL. Stock n-butylamine samples were prepared by diluting 213 L into 250 mL of diluent, where the diluent was either water, 0.1M NaOH, or DMSO. Analysis samples were further diluted 1 mL into 25 mL with the appropriate diluent for the experiment (different ratios of DMSO:0.1M NaOH or water). This dilution resulted in a final n-butylamine concentration of 0.0252 mg/mL. Stock allylamine samples were prepared by diluting 300 L into 100 mL of diluent, where the diluent was either 0.001M NaOH, 0.01M NaOH, DMF (or DMSO), or ratios of DMF (or DMSO):base. Analysis samples were further diluted 1 mL into 100 mL with the appropriate diluent for the experiment. This dilution resulted in a final allylamine concentration of 0.0228 mg/mL.


Figure 2
GC method for TEA and n-butylamine: Three minutes isothermal at 50 C, followed by a programmed temperature ramp at 20 C/min to 130 C, a hold period for 2 min, followed by a programmed ramp at 20 C/m into 170 C, a hold period for 3 min, followed by a ramp at 30 C/min to 240 C, with a four-minute hold period at the end of the temperature ramp. The injector temperature was 200 C, and the detector (i.e., FID) temperature was 300 C with a constant column flow of 3.8 mL/min of helium.


Figure 3
GC method for allylamine: Eight minutes isothermal at 45C, followed by a programmed temperature ramp at 40 C/min to 240 C, with a four-minute hold period at the end of the temperature ramp. The injector temperature was 180 C, and the detector (i.e., FID) temperature was 300 C with a constant column flow of 3.8 mL/min of helium. Headspace parameters are shown in Table I.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here